Shares of Ardelyx Inc. (ARDX) soared 5.11% on Wednesday, November 1, after the biopharmaceutical company reported strong third-quarter financial results, driven by robust revenue growth and better-than-expected earnings.
The company's total revenue for the quarter ended September 30, 2024, surged 74.2% year-over-year to $98.2 million, exceeding analysts' expectations of $86.64 million. This impressive growth was fueled by increased sales of Ardelyx's two key products, IBSRELA and XPHOZAH.
IBSRELA, a treatment for irritable bowel syndrome with constipation (IBS-C), saw its net product sales nearly double compared to the same period last year, reaching $40.6 million. The sales growth was further bolstered by a 15% increase from the second quarter of 2024, highlighting the product's strong demand and market acceptance.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。